RT Journal Article
SR Electronic
T1 Preventing herpes zoster in immunocompromised patients: Current concepts
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 437
OP 445
DO 10.3949/ccjm.91a.24019
VO 91
IS 7
A1 Calabrese, Cassandra
A1 Kirchner, Elizabeth
A1 Fernandez, James
A1 Calabrese, Leonard H.
YR 2024
UL http://www.ccjm.org/content/91/7/437.abstract
AB Herpes zoster (HZ) incidence is much higher in immunocompromised individuals than in immunocompetent individuals. HZ also occurs at a younger age and is often more severe in immunocompromised persons. Preventive strategies center around the recombinant zoster vaccine (RZV), which is approved for immunocompromised adults age 19 and older. Identifying those at greatest risk is critical. For those considering vaccination, evidence gaps regarding vaccine efficacy, toxicity, length of protection, and potential effects on underlying conditions may complicate shared and informed decision-making. Recent data have filled some of these gaps, with several societies issuing recommendations regarding vaccination. Remaining gaps are currently addressed by expert opinion.